Therefore, it is necessary to investigate NSE and ProGRP levels to evaluate the efficacy of neoadjuvant PD-(L)1 blockade plus chemotherapy in patients with LS-SCLC. The gene discussed is GRP; the disease is small cell lung carcinoma.